Key statistics
On Thursday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 379.20, -12.38% below its 52-week high of 432.80, set on Feb 18, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 386.40 |
|---|---|
| High | 389.80 |
| Low | 378.00 |
| Bid | 379.20 |
| Offer | 379.20 |
| Previous close | 385.80 |
| Average volume | 380.02k |
|---|---|
| Shares outstanding | 357.41m |
| Free float | 198.60m |
| P/E (TTM) | 297.50 |
| Market cap | 137.89bn SEK |
| EPS (TTM) | 1.30 SEK |
Data delayed at least 15 minutes, as of Mar 12 2026 17:00 BST.
More ▼
- Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
- Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
